Prophylaxis after Exposure to Coxiella burnetii

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Moodie, Claire E. ; Thompson, Herbert A. ; Meltzer, Martin I. ; Swerdlow, David L.
• Description:
  Coxiella burnetii is a category B bioterrorism agent. We numerically evaluated the risks and benefits from postexposure prophylaxis (PEP) after an intentional release of C. burnetii to the general population, pregnant women, and other high-risk populations. For each group, we constructed a decision tree to estimate illness and deaths averted by use of PEP/100,000 population. We calculated the threshold points at which the number of PEP-related adverse events was equal to the cases averted. PEP was defined as doxycycline (100 mg 2x/day for 5 days), except for pregnant women, where we assumed a PEP of trimethoprim-sulfamethoxazole (160 mg/800 mg 2x/day) for the duration of the pregnancy. PEP would begin 8-12 days postexposure. On the basis of upper-bound probability estimates of PEP-related adverse events for doxycycline, we concluded that the risk for Q fever illness outweighs the risk for antimicrobial drug-related adverse events when the probability of C. burnetii exposure is >or=7% (pregnant women using trimethoprim-sulfamethoxazole = 16%).
• Subjects:
  • Research
  • Coxiella burnetti
  • Q fever
  • prophylaxis
  • risk-benefit assessment
  • pregnant women
  • research
  • Adult
  • Anti-Bacterial Agents
  • Bioterrorism
  More +
• Source:
  Emerg Infect Dis. 14(10):1558-1566
• Pubmed ID:
  18826819
• Pubmed Central ID:
  PMC2609859
• Document Type:
  Journal Article
• Volume:
  14
• Issue:
  10
• Download URL:
  https://stacks.cdc.gov/view/cdc/3208/cdc_3208_DS1.pdf
• File Type:
  [PDF - 176.89 KB]
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha-512:ecd766d37945aea96155fd38acea900c5604d4b92603164d3a766b67700eef07d1d3854b803700c299cac6b0b87a61cd38474d87b6e3d7f8126e969764116323